HAS-BLED score (also searched as HAS BLED score, HASBLED score, ICD-10: Z92.1) is an established clinical risk prediction model designed to estimate the 1-year risk of major bleeding—specifically intracranial haemorrhage, life-threatening bleeding, and bleeding requiring hospitalisation or transfusion—in patients with atrial fibrillation receiving oral anticoagulant therapy 1,2. Developed to balance the thromboembolic protection conferred by vitamin K antagonists and direct oral anticoagulators against their inherent haemorrhagic hazards, the acronym represents nine clinical components assigned specific point values: Hypertension, Abnormal renal and liver function, Stroke history, Bleeding predisposition, Labile INR, Elderly age (greater than 65 years), and concurrent Drugs or alcohol use 1,4. By systematically categorising haemorrhagic vulnerability, the HAS-BLED score equips clinicians with a structured framework to identify patients who derive the greatest net clinical benefit from targeted risk factor modification and intensified clinical surveillance 2,5.

Etiology & Risk Factors

  • Underlying Arrhythmia: Non-valvular atrial fibrillation representing the primary clinical indication for oral anticoagulation, where thromboembolic stroke prevention must be weighed against bleeding hazards2,4.
  • Systemic Hypertension: Uncontrolled or poorly managed systolic blood pressure exceeding 160 mmHg, serving as a primary driver of cerebral microvascular rupture and gastrointestinal haemorrhage1,5.
  • Hepatic and Renal Impairment: Chronic kidney disease with advanced estimated glomerular filtration rate reduction and chronic liver disease resulting in impaired synthesis of coagulation factors and altered drug clearance1,6.
  • Cerebrovascular and Structural Vulnerability: History of prior ischaemic or haemorrhagic stroke, transient ischaemic attack, or structural cerebral microbleeds predisposing to catastrophic intracranial bleeding1,2.
  • Haemostatic Deficiencies: Prior major bleeding episodes, inherited or acquired bleeding diathesis, and severe thrombocytopenia compromising primary and secondary haemostasis1,3.
  • Pharmacological and Toxic Exposures: Concomitant use of antiplatelet agents (e.g., aspirin, clopidogrel), non-steroidal anti-inflammatory drugs (NSAIDs), and chronic harmful alcohol consumption impairing platelet function and gastric mucosal integrity1,4.

Pathophysiology

The pathophysiological basis of the HAS-BLED score centres on the cumulative impairment of vascular integrity, haemostatic reserve, and pharmacological clearance mechanisms. Chronic hypertension induces vascular remodelling, lipohyalinosis, and microaneurysm formation within cerebral penetrating arteries, sharply elevating the risk of spontaneous intracerebral haemorrhage upon anticoagulation exposure. Concomitant renal or hepatic dysfunction disrupts the pharmacokinetics of antithrombotic agents—leading to drug accumulation and excessive anticoagulation effect—while concurrently reducing the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and circulating platelets. Previous cerebrovascular insults reflect preexisting cerebral small vessel disease, rendering the brain parenchyma exceptionally vulnerable to secondary haemorrhagic transformation. Furthermore, exogenous agents such as antiplatelets and NSAIDs inhibit platelet aggregation and erode gastrointestinal mucosal defenses, synergising with anticoagulants to precipitate overt gastrointestinal bleeding. Labile INRs reflect unstable hepatic metabolism or dietary vitamin K fluctuations, resulting in prolonged periods above the therapeutic window where bleeding risk escalates exponentially.

HAS-BLED score — Pathophysiological Cascade & Clinical Flowchart 1 Clinical Baseline Baseline patient evaluation for atrial fibrillation and antithrombotic therapy indication 2 Risk Component Analysis Accumulation of points across hypertension, renal, hepatic, stroke, bleeding, labile INR, elderly, and drug/alcohol domains 3 Bleeding Vulnerability Assessment of cumulative haemorrhagic potential and mucosal or intracranial susceptibility 4 Risk Stratification Categorisation into low, intermediate, or high risk (score >= 3 indicating high bleeding risk) 5 Therapeutic Optimization Correction of modifiable risk factors and scheduling of frequent clinical reviews without withholding necessary anticoagulation

Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients with elevated bleeding risk often present with insidious or acute haemorrhagic manifestations, including recurrent epistaxis, spontaneous ecchymoses, melaena, haematochezia, frank haematuria, or sudden focal neurological deficits indicative of intracranial haemorrhage1,3. Detailed medication reconciliation frequently reveals unprescribed NSAID use or chronic excessive alcohol intake1,4.
  • Physical Examination & Named Clinical Signs: Examination may reveal persistent systolic hypertension exceeding 160 mmHg, scleral icterus or hepatomegaly suggesting chronic liver disease, cutaneous purpura or petechiae reflecting primary haemostatic failure, or postural dizziness and pallor secondary to occult blood loss and anaemia1,5.

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationComprehensive clinical evaluation combined with validated HAS-BLED risk scoring and serial laboratory assessment to quantify bleeding vulnerability and identify modifiable contributors 1,4.
Laboratory PanelComplete blood count demonstrating baseline anaemia or thrombocytopenia; serum creatinine and estimated glomerular filtration rate (eGFR) assessing renal function; liver function tests (bilirubin, transaminases, albumin) evaluating hepatic synthetic capacity; and coagulation profiles (PT/INR, aPTT) establishing baseline haemostasis 1,6.
Imaging / Radiology (X-ray, US, CT, MRI)Non-contrast computed tomography (CT) or magnetic resonance imaging (MRI) of the brain indicated upon acute neurological deterioration to rule out intracranial haemorrhage; abdominal ultrasound evaluating hepatic parenchymal architecture and portal hypertension 1,5.
ECG / Histopathology / Procedural12-lead electrocardiogram confirming the diagnosis of atrial fibrillation; serial faecal occult blood testing or endoscopic evaluation (oesophagogastroduodenoscopy, colonoscopy) when occult gastrointestinal blood loss is suspected 2,3.

Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
H — HypertensionUncontrolled systolic blood pressure greater than 160 mmHg (1 point). Requires aggressive antihypertensive therapy and close blood pressure monitoring 1,5.
A — Abnormal Renal FunctionChronic dialysis, renal transplantation, or serum creatinine greater than 2.26 mg/dL (200 micromol/L) (1 point). Mandates dose adjustment and renal surveillance 1,6.
A — Abnormal Liver FunctionChronic hepatic disease (e.g., cirrhosis) or biochemical evidence of significant hepatic derangement (e.g., bilirubin greater than 2 times upper limit of normal, AST/ALT/AP greater than 3 times upper limit of normal) (1 point) 1,6.
S — Stroke HistoryPrior ischaemic or haemorrhagic stroke, or transient ischaemic attack (1 point). Reflects underlying cerebral vasculopathy 1,2.
B — Bleeding PredispositionPrior major bleeding history or known bleeding diathesis/anaemia predisposition (1 point). Highlights intrinsic haemostatic compromise 1,3.
L — Labile INRUnstable or labile INRs, or poor time in therapeutic range (TTR less than 60%) for patients on vitamin K antagonists (1 point) 1,2.
E — ElderlyAge strictly greater than 65 years (1 point). Captures age-related physiological decline and vascular stiffening 1,4.
D — Drugs or Alcohol ConcomitantlyConcurrent use of antiplatelet agents, non-steroidal anti-inflammatory drugs, or chronic harmful alcohol consumption (1 or 2 points depending on criteria) 1,4.
Total Score & InterpretationScores range from 0 to 9. A score of 3 or greater indicates "high risk" for major bleeding, serving as an alert to aggressively correct modifiable risk factors rather than withhold anticoagulation 2,5.

Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
CHA2DS2-VASc ScoreFocuses exclusively on assessing thromboembolic and stroke risk in atrial fibrillation rather than evaluating haemorrhagic complications. Uses distinct clinical variables (e.g., congestive heart failure, vascular disease, diabetes) 2,4.
ORBIT Bleeding Risk ScoreAlternative bleeding risk prediction model incorporating older age, anaemia, bleeding history, renal function, and antiplatelet treatment, often demonstrating specific calibration profiles in anticoagulated cohorts 3.
ACUTE Gastrointestinal HaemorrhagePresents with overt melaena or haematemesis; differentiation relies on endoscopic visualisation of peptic ulcer disease, angiodysplasia, or malignancy rather than systemic risk scores alone 1,3.
Inherited Coagulopathies (e.g., Haemophilia, von Willebrand Disease)Characterised by lifelong history of abnormal bruising and spontaneous deep tissue or joint bleeding, distinguished by specific factor assays and normal platelet counts (in von Willebrand) 1,6.

Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate cessation of oral anticoagulation and antiplatelet agents in the event of major or life-threatening bleeding. Administration of reversal agents (e.g., prothrombin complex concentrate and vitamin K for vitamin K antagonists; idarucizumab for dabigatran; and andexanet alfa for factor Xa inhibitors) alongside supportive fluid resuscitation and packed red blood cell transfusion as clinically indicated1,2.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing): Aggressive blood pressure control targeting systolic blood pressure strictly below 130–140 mmHg using guideline-directed medical therapy. Optimization of renal and hepatic function, cessation of concurrent non-steroidal anti-inflammatory drugs, and alcohol reduction counselling2,5. For patients with elevated HAS-BLED scores requiring anticoagulation, direct oral anticoagulators (e.g., apixaban 5 mg orally twice daily, adjusted to 2.5 mg twice daily if meeting two of age greater than or equal to 80 years, body weight less than or equal to 60 kg, or serum creatinine greater than or equal to 1.5 mg/dL) are frequently favoured over vitamin K antagonists due to lower intracranial bleeding rates2,3.
  • Surgical / Interventional Indications: Urgent endoscopic intervention for actively bleeding gastrointestinal lesions; neurosurgical decompression or stereotactic evacuation for life-threatening intracranial haemorrhage with mass effect; and left atrial appendage occlusion (e.g., Watchman procedure) in patients with atrial fibrillation and absolute contraindications to long-term oral anticoagulation1,2.

Complications & Prognosis

  • Major Haemorrhagic Events: Occurrence of fatal or disabling intracranial haemorrhage, severe gastrointestinal blood loss requiring blood transfusions, and retroperitoneal or muscular haematomas1,3.
  • Thromboembolic Sequelae: Ischaemic stroke, systemic arterial embolism, and transient ischaemic attacks arising secondary to inappropriate discontinuation or withholding of oral anticoagulation due to misinterpreted high bleeding risk scores2,4.
  • Prognostic Factors: Prognosis is dictated by the prompt identification and correction of modifiable HAS-BLED risk components (such as hypertension and labile INRs) and the maintenance of structured clinical follow-up every 4 to 12 weeks to ensure therapeutic compliance and minimise adverse clinical outcomes2,5.